Skip Navigation
Skip to contents

Ann Coloproctol : Annals of Coloproctology

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > Ann Coloproctol > Volume 42(5); 2026 > Article
Original Article
Colorectal cancer
Transverse colon cancer as an independent predictor of locoregional recurrence in patients with stage III colon cancer: a retrospective cohort study
Min Hyeong Jo1orcid, Kyong-Min Kang2orcid, Mi Jeong Choi2orcid, Hye-Rim Shin2orcid, Tae-Gyun Lee3orcid, Hong-Min Ahn2orcid, Heung-Kwon Oh2orcid, Duck-Woo Kim2orcid, Sung-Bum Kang2orcid
Annals of Coloproctology 2026;42(5):545-552.
DOI: https://doi.org/10.3393/ac.2026.00325.0046
Published online: October 1, 2026

1Department of Surgery, Ewha Womans University College of Medicine, Seoul, Korea

2Department of Surgery, Seoul National University Bundang Hospital, Seongnam, Korea

3Department of Surgery, Ajou University School of Medicine, Suwon, Korea

Correspondence to: Sung-Bum Kang, MD, PhD Department of Surgery, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea Email: kangsb@snubh.org
• Received: March 11, 2026   • Revised: June 17, 2026   • Accepted: June 22, 2026

© 2026 The Korean Society of Coloproctology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next
  • 979 Views
  • 19 Download
  • Purpose
    This study aimed to evaluate the significance of transverse colon cancer as a predictor of locoregional recurrence in patients with stage III colon cancer.
  • Methods
    This single-center retrospective cohort study included 1,302 patients who underwent curative-intent laparoscopic colectomy for stage III colon cancer between 2003 and 2021. The primary outcome was locoregional recurrence, defined as tumor recurrence near the anastomotic site, regional lymph nodes, or peritoneal recurrence around the primary tumor. Multivariate analyses were conducted to identify the factors associated with locoregional recurrence.
  • Results
    Transverse colon cancer was identified in 151 patients (11.6%). Baseline characteristics were similar, but transverse colon cancer exhibited a higher locoregional recurrence rate than nontransverse colon cancer (7.9% vs. 2.0%, P<0.001). In transverse colon cancer, locoregional recurrence did not differ according to high ligation of the mid-colic vessel (without high ligation, 10.6% vs. high ligation, 6.7%; P=0.517), and 10 of 12 recurrences (83.3%) occurred predominantly in the regional lymph nodes. In multivariate analysis, transverse colon (hazard ratio [HR], 4.513; 95% confidence interval [CI], 2.226–9.154; P<0.001) and N2 category (HR, 2.044; 95% CI, 1.034–4.042; P=0.040) emerged as independent predictors of locoregional recurrence. Disease-free survival (73.8% vs. 79.2%, P=0.217) and overall survival (84.7% vs. 86.3%, P=0.735) in 5 years were not different between transverse and nontransverse colon cancer.
  • Conclusion
    Transverse colon cancer may serve as an independent predictor of locoregional recurrence in stage III colon cancer. The predominance of regional lymph node recurrence emphasizes the importance of careful regional lymph node assessment in transverse colon cancer.
The initial draft of this graphical abstract was generated using generative artificial intelligence. It was subsequently reviewed, revised, and confirmed by the authors, editors, and publisher to ensure its accuracy and consistency with the content of the article.
Colorectal cancer is one of the most commonly diagnosed malignancies worldwide, with approximately 1.9 million new cases estimated in 2022, accounting for 9.6% of all cancer cases [1]. Transverse colon cancer, which accounts for less than 10% of all colon cancers, is relatively rare [2]. Anatomically, the colon from the hepatic flexure to the splenic flexure is classified as the transverse colon [3]. Transverse colon cancer is characterized by its close proximity to adjacent organs, including the stomach, pancreas, liver, and spleen, as well as its unpredictable lymphatic drainage to the superior mesenteric artery and inferior mesenteric artery territories [4]. These features contribute to unpredictable patterns of tumor spread and make surgical management particularly challenging. Although transverse colon cancer has been reported to be associated with worse oncologic outcomes compared with other colon segments [5, 6], these previous studies included a wide range of cancer stages and also encompassed emergency surgeries, which limited the accurate assessment of the oncologic risk of transverse colon cancer. Additionally, the surgical strategy for transverse colon cancer remains controversial, especially regarding whether to perform segmental (transverse colectomy) or extended resection, as different studies have reported conflicting results [7–10].
This study focused on patients with stage III colon cancer, in which nodal involvement increases the risk of locoregional recurrence, making locoregional control particularly important [11, 12]. By targeting this high-risk group, we aimed to evaluate the significance of transverse colon cancer as a predictor of locoregional recurrence in patients with stage III colon cancer.
Ethics statement
This study was approved by the Institutional Review Board of Seoul National University Bundang Hospital (No. B-2502-957-104). The requirement for informed consent was waived due to the use of deidentified data and the retrospective nature of the study.
Patients
This retrospective cohort study included patients who underwent surgery for colon cancer at a single tertiary referral center between January 2003 and December 2021. To maintain consistency in the surgical techniques and oncologic outcomes, only patients who underwent laparoscopic surgery were included.
Stage III colon cancer patients were selected to focus on the high-risk population for nodal metastasis. Patients with tumors located between the hepatic flexure and the splenic flexure were categorized into the transverse colon cancer group, whereas those with tumors in the ascending colon, descending colon, or sigmoid colon were categorized into the nontransverse colon cancer group.
Outcomes
The primary outcome of this study was the locoregional recurrence rate, defined as tumor recurrence occurring near the anastomotic site, in regional lymph nodes, or as peritoneal recurrence around the primary tumor [12–14]. Secondary outcomes included disease-free survival (DFS), defined as the time from surgery to the first documented recurrence (locoregional or systemic) or death from any cause, and overall survival (OS), defined as the time from surgery to death from any cause [15]. Postoperative surveillance was performed according to an institutional protocol based on National Comprehensive Cancer Network (NCCN) guidelines and did not differ according to tumor location. Physical examination and serum carcinoembryonic antigen (CEA) measurement were performed every 3–6 months, and computed tomography (CT) of the chest, abdomen, and pelvis was performed every 6–12 months, for at least 5 years after surgery. Positron emission tomography/CT was not performed routinely and was reserved for cases requiring further characterization of indeterminate lesions suspected of being metastatic on CT.
Data collection
Baseline demographic and clinical characteristics, including age, sex, body mass index (BMI), and American Society of Anesthesiologists (ASA) physical status, were recorded. Data on preoperative serum CEA levels and mid-colic vessel ligation status were collected. The 30-day postoperative complication rates were also assessed. The pathological data included T and N categories, resection margins, specimen length, number of harvested lymph nodes, number of metastatic lymph nodes, and presence of lymphovascular and perineural invasion. Data on adjuvant chemotherapy and recurrence, including locoregional and systemic recurrences, were collected from follow-up records.
Statistical analysis
Categorical variables were compared using the chi-square test or the Fisher exact test, and continuous variables were analyzed using the Student t-test or Mann-Whitney U-test, as appropriate. Survival outcomes were estimated using the Kaplan-Meier method, and differences between groups were assessed using the log-rank test. Univariate and multivariate Cox proportional hazards regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) to identify independent predictors of locoregional recurrence. Variables included in the multivariate model were selected based on statistical significance in univariate analysis (P<0.1) or clinical relevance, with the number of variables limited in consideration of the number of events to minimize the risk of model instability. Variables showing substantial correlations with other covariates were excluded from the multivariate model to avoid potential multicollinearity. All statistical analyses were conducted using IBM SPSS ver. 27.0 (IBM Corp). Descriptive results for continuous variables are expressed as mean±standard deviation or median (interquartile range), as appropriate. A P-value of <0.05 was considered statistically significant.
Overall, 5,516 patients with colon cancer were screened for eligibility; of these, 1,237 underwent open surgery, and 2,977 were diagnosed with stage I, II, or IV colon cancer, and 1,302 patients with stage III colon cancer who underwent laparoscopic surgery were included in the final analysis. Among these, 151 patients (11.6%) had transverse colon cancer, and 1,151 patients (88.4%) had nontransverse colon cancer.
The baseline demographic and clinical characteristics, including age, sex, BMI, ASA physical status, preoperative CEA levels, 30-day complication rates, and the rates of adjuvant chemotherapy, were comparable between the 2 groups (Table 1). Among 151 patients with transverse colon cancer, only 2 underwent transverse colectomy, whereas 149 underwent extended resection. In pathologic outcomes, the proportion of N2 category was significantly higher in the nontransverse colon cancer group, whereas the transverse colon cancer group had more harvested lymph nodes. The proximal and distal resection margins and length of the specimens were significantly longer in the transverse colon cancer group. High-risk features, including lymphatic, venous, and perineural invasions, did not differ significantly between the 2 groups (Table 2). Patients with fewer than 12 harvested lymph nodes were extremely rare, with only 4 cases (0.3%) observed in the nontransverse colon cancer group.
The locoregional recurrence rate was significantly higher in the transverse colon cancer group compared with the nontransverse colon cancer group (7.9% vs. 2.0%, P<0.001). In transverse colon cancer, 10 of 12 locoregional recurrences (83.3%) occurred predominantly in the regional lymph nodes, whereas in nontransverse colon cancer, the most common site of locoregional recurrence was near the anastomotic site (12 of 23, 52.2%) (Table 3). Systemic recurrence occurred in 126 patients (10.9%) in the nontransverse colon cancer group and in 19 patients (12.6%) in the transverse colon cancer group, without a significant difference (P=0.548). In transverse colon cancer, locoregional recurrence did not differ significantly according to high ligation of the mid-colic vessel (without high ligation, 10.6% [5 of 47] vs. high ligation, 6.7% [7 of 104]; P=0.517). In the multivariate analysis, the transverse colon (HR, 4.513; 95% CI, 2.226–9.154; P<0.001) and N2 category (HR, 2.044; 95% CI, 1.034–4.042; P=0.040) were identified as independent predictors of locoregional recurrence (Table 4).
The median follow-up period was 64.2 months (interquartile range, 43.2–96.2). Kaplan-Meier survival analysis revealed no significant differences in the 5-year DFS and OS between the 2 groups (Fig. 1). The 5-year DFS was 73.8% for transverse colon cancer and 79.2% for nontransverse colon cancer (P=0.217), and the 5-year OS was 84.7% and 86.3%, respectively (P=0.735).
This study identified transverse colon cancer as an independent predictor of locoregional recurrence in patients with stage III colon cancer who underwent laparoscopic surgery. In multivariate analysis, tumor location in the transverse colon demonstrated a higher HR than advanced nodal status, a well-recognized predictor of recurrence [16–19]. These findings may have important implications for surgical planning and locoregional control in patients with stage III transverse colon cancer.
The majority of locoregional recurrences in transverse colon cancer occurred in the regional lymph nodes. Such recurrence patterns may be explained by the anatomical complexity of the transverse colon and its variable lymphatic drainage to multiple vascular territories [4], which may increase the risk of locoregional recurrence compared with colon cancer in other locations. Previous studies reporting worse oncologic outcomes in transverse colon cancer have also suggested that these characteristics contribute to poor prognosis [6, 7, 20]. Such features may be more closely associated with locoregional recurrence than with overall oncologic outcomes.
Although the locoregional recurrence rate was significantly higher in the transverse colon cancer group than in the nontransverse colon cancer group, this did not result in a significant difference in survival outcomes between the groups. Several factors may have contributed to this discordance. First, locoregional recurrence represents a minority of overall recurrence events, accounting for approximately 20% of all recurrences. Systemic recurrence constituted most recurrence events, with no significant differences between the groups, potentially diluting the impact of higher locoregional recurrence rates in transverse colon cancer on DFS and OS. A similar dissociation between locoregional recurrence and survival outcomes has been reported in rectal cancer, where preoperative chemoradiotherapy reduced locoregional recurrence compared with postoperative chemoradiotherapy without improving survival outcomes [21, 22]. Second, the relatively small number of locoregional recurrence events in the transverse colon cancer group (n=12) may have limited the statistical power to detect a survival difference attributable to locoregional recurrence. Nevertheless, these findings remain clinically significant and warrant attention, as locoregional recurrence is associated with increased treatment burden and may adversely affect patient quality of life, even in the absence of survival differences.
The surgical strategy for transverse colon cancer remains an unresolved issue, with some studies reporting comparable oncologic outcomes between segmental and extended resections [7, 23–26], whereas one study suggested favorable outcomes with extended resection [20]. In our institution, extended resection has been routinely performed for transverse colon cancer except in selected cases. Accordingly, a direct comparison of oncologic outcomes according to surgical strategy was not feasible in the present study. There was no significant difference in locoregional recurrence according to high ligation of the mid-colic vessel. Given the absence of an established standard surgical procedure for mid-colic vessel ligation in transverse colon cancer, high ligation may be selectively performed based on tumor location or intraoperative findings. Instead, the higher locoregional recurrence rate observed in transverse colon cancer may suggest the potential benefit of meticulous regional lymph node dissection to achieve adequate locoregional control in this subgroup. However, given the lack of a significant association between high ligation of the mid-colic vessel and locoregional recurrence, further studies are needed to determine whether more extensive regional lymph node dissection can improve locoregional control in transverse colon cancer. Nevertheless, comprehensive preoperative evaluation of enlarged regional lymph nodes on CT may be considered in determining the appropriate extent of lymphadenectomy for suspected metastatic lymph nodes. In this context, techniques such as preoperative indocyanine green–guided lymphatic mapping may help tailor regional lymph node dissection in transverse colon cancer, although their oncologic impact requires further evaluation [27–29].
Limitations
This study has several limitations. First, the retrospective nature of the study may have introduced an inherent selection bias. However, by including only patients with stage III colon cancer who underwent laparoscopic surgery, we attempted to strengthen cohort homogeneity and reduce variability. Second, the number of locoregional recurrence events was limited, especially in the transverse colon cancer group (n=12), which restricted the number of variables that could be included in the multivariate Cox regression model and may pose a potential risk of model instability. The results of the multivariate analysis should be interpreted with caution, and validation in larger prospective cohorts is warranted.
Conclusions
This study demonstrated that transverse colon cancer may serve as an independent predictor of locoregional recurrence in patients with stage III colon cancer who underwent laparoscopic surgery. The predominance of regional lymph node recurrence in transverse colon cancer emphasizes the importance of careful regional lymph node assessment for locoregional control in this group.

Conflict of interest

Hong-Min Ahn is an editorial board member of this journal, but was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflict of interest relevant to this article was reported.

Funding

This study was supported by the Seoul National University Bundang Hospital research fund (No. 14-2021-0030).

Acknowledgments

The authors gratefully acknowledge the contributions of the clinical research coordinators and nursing staff of the Department of Surgery at Seoul National University Bundang Hospital for their assistance in data collection and patient care.

Author contributions

Conceptualization: MHJ, SBK; Data curation: KMK, MJC, HRS, TGL, HMA, HKO, DWK; Formal analysis: MHJ, SBK; Funding acquisition: SBK; Investigation: KMK, MJC, HRS, TGL, HMA, HKO, DWK; Methodology: MHJ, SBK; Project administration: MHJ, SBK; Writing–original draft: MHJ, SBK; Writing–review & editing: all authors. All authors read and approved the final manuscript.

Additional information

This study was previously presented as an oral presentation at the 54th Congress of the Korean Society of Endo-Laparoscopic and Robotic Surgery (KSERS) and the 14th International Symposium on April 11–13, 2024, in Daejeon, Korea, and as an e-poster at the 2024 Annual Scientific Meeting of the American Society of Colon and Rectal Surgeons (ASCRS), on June 1–4, 2024, in Baltimore, MD, USA.

Fig. 1.
Kaplan-Meier curves for (A) disease-free survival and (B) overall survival in the nontransverse and transverse colon cancer groups.
ac-2026-00325-0046f1.jpg
ac-2026-00325-0046f2.jpg
Table 1.
Baseline characteristics (n=1,302)
Characteristic Nontransverse colon cancer (n=1,151) Transverse colon cancer (n=151) P-value
Age (yr) 63.8±11.9 65.2±12.9 0.200
 ≤65 607 (52.7) 73 (48.3) 0.314
 >65 544 (47.3) 78 (51.7)
Sex 0.332
 Male 635 (55.2) 77 (51.0)
 Female 516 (44.8) 74 (49.0)
BMI (kg/m2) 23.9±3.4 23.8±3.0 0.557
ASA physical status 0.280
 I 336 (29.2) 38 (25.2)
 II 706 (61.3) 95 (62.9)
 III 105 (9.1) 18 (11.9)
 IV 4 (0.3) 0 (0)
Preoperative CEA (ng/mL) 2.6 (1.5–5.9) 2.1 (1.3–4.5) 0.098
Tumor location - -
 Ascending colon 340 (29.5)
 Descending colon 68 (5.9)
 Sigmoid colon 743 (64.6)
30-Day complication 112 (9.7) 22 (14.6) 0.069
Adjuvant chemotherapy 1,048 (91.1) 138 (91.4) 0.917

Values are presented as mean±standard deviation, number (%), or median (interquartile range).

BMI, body mass index; ASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen

Table 2.
Pathological data (n=1,302)
Variable Nontransverse colon cancer (n=1,151) Transverse colon cancer (n=151) P-value
T category 0.331
 T1–T2 163 (14.2) 17 (11.3)
 T3–T4 988 (85.8) 134 (88.7)
N category 0.048
 N1 794 (69.0) 116 (76.8)
 N2 357 (31.0) 35 (23.2)
No. of harvested lymph nodes 42.3±20.5 56.0±28.2 <0.001
No. of metastatic lymph nodes 3.4±4.0 2.8±3.2 0.070
Proximal resection margin (cm) 12.1±10.7 23.7±13.5 <0.001
Distal resection margin (cm) 9.9±8.8 13.3±12.1 0.001
Length of specimen (cm) 21.8±15.5 36.8±15.3 <0.001
Lymphatic invasiona 0.825
 No 582 (50.7) 78 (51.7)
 Yes 566 (49.3) 73 (48.3)
Venous invasiona 0.145
 No 833 (72.6) 118 (78.1)
 Yes 315 (27.4) 33 (21.9)
Perineural invasiona 0.340
 No 487 (42.4) 70 (46.7)
 Yes 661 (57.6) 80 (53.3)

Values are presented as number (%) or mean±standard deviation.

aData on lymphatic, venous, and perineural invasion were unavailable for 3 patients in the nontransverse colon cancer group, and perineural invasion data were unavailable for 1 patient in the transverse colon cancer group, due to incomplete pathological records.

Table 3.
Recurrence patterns by colon cancer location (n=1,302)
Recurrence pattern No. of patients (%) P-value
Nontransverse colon cancer (n=1,151) Transverse colon cancer (n=151)
Locoregional recurrence 23 (2.0) 12 (7.9) <0.001
 Near the anastomotic site 12 (1.0) 1 (0.7)
 Regional lymph nodes 4 (0.3) 10 (6.6)
 Peritoneal recurrence around the primary tumor 7 (0.6) 1 (0.7)
Systemic recurrencea 126 (10.9) 19 (12.6) 0.548
 Liver 48 (4.2) 8 (5.3)
 Lung 48 (4.2) 8 (5.3)
 Distant lymph nodes 19 (1.7) 4 (2.6)
 Multiple peritoneal seeding 17 (1.5) 1 (0.7)
 Otherb 12 (1.0) 3 (2.0)

Combined systemic and locoregional recurrence was detected in 8 patients in the nontransverse colon cancer group and in 4 patients in the transverse colon cancer group.

aPatients could have recurrence at more than one systemic site. bIncluding the ovaries, spleen, small bowel, adrenal gland, ureter, and bone.

Table 4.
Univariate and multivariate Cox regression analysis for locoregional recurrence
Variable Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Age >65 yr 1.192 (0.608–2.335) 0.609 1.144 (0.582–2.246) 0.697
Female sex 1.032 (0.530–2.006) 0.927 1.024 (0.522–2.011) 0.945
ASA physical status III–IV 1.695 (0.657–4.368) 0.275
CEA >5 ng/mL 1.191 (0.567–2.502) 0.644
Transverse colon 4.130 (2.055–8.299) <0.001 4.513 (2.226–9.154) <0.001
T3–T4 category 5.733 (0.785–41.883) 0.085 4.220 (0.569–31.325) 0.159
N2 category 1.985 (1.021–3.860) 0.043 2.044 (1.034–4.042) 0.040
Adjuvant chemotherapy 2.146 (0.831–5.539) 0.114
Proximal resection margin <5 cm 0.381 (0.091–1.586) 0.185
Distal resection margin <5 cm 1.029 (0.518–2.043) 0.935
Lymphatic invasion 2.004 (0.997–4.028) 0.051
Venous invasion 2.122 (1.087–4.145) 0.028
Perineural invasion 2.570 (1.168–5.658) 0.019

Lymphatic, venous, and perineural invasion were excluded from the multivariate analysis to avoid potential multicollinearity in consideration of the limited number of events.

HR, hazard ratio; CI, confidence interval; ASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen.

  • 1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229–63. ArticlePubMed
  • 2. Guan X, Zhao Z, Yang M, Chen H, Chen W, Liu Z, et al. Whether partial colectomy is oncologically safe for patients with transverse colon cancer: a large population-based study. Oncotarget 2017;8:93236–44. ArticlePubMedPMC
  • 3. Schlachta CM, Mamazza J, Poulin EC. Are transverse colon cancers suitable for laparoscopic resection? Surg Endosc 2007;21:396–9. ArticlePubMedPDF
  • 4. Li C, Wang Q, Jiang KW. What is the best surgical procedure of transverse colon cancer? An evidence map and minireview. World J Gastrointest Oncol 2021;13:391–9. ArticlePubMedPMC
  • 5. Zenger S, Gurbuz B, Can U, Erginoz E, Ozata IH, Kulle CB, et al. Mid-transverse location in primary colon tumor: a poor prognostic factor? Dis Colon Rectum 2022;65:817–26. ArticlePubMed
  • 6. Sjo OH, Lunde OC, Nygaard K, Sandvik L, Nesbakken A. Tumour location is a prognostic factor for survival in colonic cancer patients. Colorectal Dis 2008;10:33–40. ArticlePubMed
  • 7. Chong CS, Huh JW, Oh BY, Park YA, Cho YB, Yun SH, et al. Operative method for transverse colon carcinoma: transverse colectomy versus extended colectomy. Dis Colon Rectum 2016;59:630–9. ArticlePubMed
  • 8. van Rongen I, Damhuis RA, van der Hoeven JA, Plaisier PW. Comparison of extended hemicolectomy versus transverse colectomy in patients with cancer of the transverse colon. Acta Chir Belg 2013;113:107–11. ArticlePubMed
  • 9. Odermatt M, Siddiqi N, Johns R, Miskovic D, Khan O, Khan J, et al. Short- and long-term outcomes for patients with splenic flexure tumours treated by left versus extended right colectomy are comparable: a retrospective analysis. Surg Today 2014;44:2045–51. ArticlePubMedPDF
  • 10. Morarasu S, Clancy C, Cronin CT, Matsuda T, Heneghan HM, Winter DC. Segmental versus extended colectomy for tumours of the transverse colon: a systematic review and meta-analysis. Colorectal Dis 2021;23:625–34. ArticlePubMedPDF
  • 11. Swartjes H, van Lankveld DW, van Erning FN, Verheul HM, de Wilt JH, Koëter T, et al. Locoregionally recurrent colon cancer: how far have we come? A population-based, retrospective cohort study. Ann Surg Oncol 2023;30:1726–34. ArticlePubMedPDF
  • 12. Liska D, Stocchi L, Karagkounis G, Elagili F, Dietz DW, Kalady MF, et al. Incidence, patterns, and predictors of locoregional recurrence in colon cancer. Ann Surg Oncol 2017;24:1093–9. ArticlePubMedPDF
  • 13. Bowne WB, Lee B, Wong WD, Ben-Porat L, Shia J, Cohen AM, et al. Operative salvage for locoregional recurrent colon cancer after curative resection: an analysis of 100 cases. Dis Colon Rectum 2005;48:897–909. ArticlePubMed
  • 14. Brown KG, Koh CE. Surgical management of recurrent colon cancer. J Gastrointest Oncol 2020;11:513–25. ArticlePubMedPMC
  • 15. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23:8664–70. ArticlePubMed
  • 16. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010;28:264–71. ArticlePubMedPMC
  • 17. Ong ML, Schofield JB. Assessment of lymph node involvement in colorectal cancer. World J Gastrointest Surg 2016;8:179–92. ArticlePubMedPMC
  • 18. Kim HJ, Choi GS. Clinical implications of lymph node metastasis in colorectal cancer: current status and future perspectives. Ann Coloproctol 2019;35:109–17. ArticlePubMedPMCPDF
  • 19. Nagasaki T, Akiyoshi T, Fujimoto Y, Konishi T, Nagayama S, Fukunaga Y, et al. Prognostic impact of distribution of lymph node metastases in stage III colon cancer. World J Surg 2015;39:3008–15.ArticlePubMedPDF
  • 20. Milone M, Degiuli M, Allaix ME, Ammirati CA, Anania G, Barberis A, et al. Mid-transverse colon cancer and extended versus transverse colectomy: results of the Italian Society of Surgical Oncology Colorectal Cancer Network (SICO CCN) multicenter collaborative study. Eur J Surg Oncol 2020;46:1683–8. PubMed
  • 21. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731–40. ArticlePubMed
  • 22. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012;30:1926–33. ArticlePubMed
  • 23. Wang X, Zheng Z, Chen M, Lu X, Huang S, Huang Y, et al. Subtotal colectomy, extended right hemicolectomy, left hemicolectomy, or splenic flexure colectomy for splenic flexure tumors: a network meta-analysis. Int J Colorectal Dis 2021;36:311–22. ArticlePubMedPDF
  • 24. Milone M, Manigrasso M, Elmore U, Maione F, Gennarelli N, Rondelli F, et al. Short- and long-term outcomes after transverse versus extended colectomy for transverse colon cancer. A systematic review and meta-analysis. Int J Colorectal Dis 2019;34:201–7. ArticlePubMedPDF
  • 25. Leijssen LG, Dinaux AM, Amri R, Kunitake H, Bordeianou LG, Berger DL. A transverse colectomy is as safe as an extended right or left colectomy for mid-transverse colon cancer. World J Surg 2018;42:3381–9. ArticlePubMedPDF
  • 26. Park HM, Lee J, Lee SY, Kim CH, Kim HR. Distribution of lymph node metastasis and oncological outcomes of mid-transverse colon cancer: extended versus transverse colectomy. Colorectal Dis 2021;23:2007–13. ArticlePubMedPDF
  • 27. Wan J, Wang S, Yan B, Tang Y, Zheng J, Ji H, et al. Indocyanine green for radical lymph node dissection in patients with sigmoid and rectal cancer: randomized clinical trial. BJS Open 2022;6:zrac151.ArticlePubMedPMCPDF
  • 28. Bao Y, Gao Z, Shen K, Cao J, Yin M, Jiang K, et al. Indocyanine green fluorescence-guided lymphatic mapping improves central nodes dissection and survival in left-sided colon cancer and rectal cancer: a prospective cohort study. Int J Surg 2026;112:3348–59. ArticlePubMed
  • 29. Ueda K, Ushijima H, Kawamura J. Lymphatic flow mapping during colon cancer surgery using indocyanine green fluorescence imaging. Minim Invasive Ther Allied Technol 2023;32:233–9. ArticlePubMed

Figure & Data

References

    Citations

    Citations to this article as recorded by  

      • Cite this Article
        Cite this Article
        export Copy Download
        Close
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Transverse colon cancer as an independent predictor of locoregional recurrence in patients with stage III colon cancer: a retrospective cohort study
        Ann Coloproctol. 2026;42(5):545-552.   Published online October 1, 2026
        Close
      • XML DownloadXML Download
      Figure
      • 0
      • 1
      Related articles
      Transverse colon cancer as an independent predictor of locoregional recurrence in patients with stage III colon cancer: a retrospective cohort study
      Image Image
      Fig. 1. Kaplan-Meier curves for (A) disease-free survival and (B) overall survival in the nontransverse and transverse colon cancer groups.
      Graphical abstract
      Transverse colon cancer as an independent predictor of locoregional recurrence in patients with stage III colon cancer: a retrospective cohort study
      Characteristic Nontransverse colon cancer (n=1,151) Transverse colon cancer (n=151) P-value
      Age (yr) 63.8±11.9 65.2±12.9 0.200
       ≤65 607 (52.7) 73 (48.3) 0.314
       >65 544 (47.3) 78 (51.7)
      Sex 0.332
       Male 635 (55.2) 77 (51.0)
       Female 516 (44.8) 74 (49.0)
      BMI (kg/m2) 23.9±3.4 23.8±3.0 0.557
      ASA physical status 0.280
       I 336 (29.2) 38 (25.2)
       II 706 (61.3) 95 (62.9)
       III 105 (9.1) 18 (11.9)
       IV 4 (0.3) 0 (0)
      Preoperative CEA (ng/mL) 2.6 (1.5–5.9) 2.1 (1.3–4.5) 0.098
      Tumor location - -
       Ascending colon 340 (29.5)
       Descending colon 68 (5.9)
       Sigmoid colon 743 (64.6)
      30-Day complication 112 (9.7) 22 (14.6) 0.069
      Adjuvant chemotherapy 1,048 (91.1) 138 (91.4) 0.917
      Variable Nontransverse colon cancer (n=1,151) Transverse colon cancer (n=151) P-value
      T category 0.331
       T1–T2 163 (14.2) 17 (11.3)
       T3–T4 988 (85.8) 134 (88.7)
      N category 0.048
       N1 794 (69.0) 116 (76.8)
       N2 357 (31.0) 35 (23.2)
      No. of harvested lymph nodes 42.3±20.5 56.0±28.2 <0.001
      No. of metastatic lymph nodes 3.4±4.0 2.8±3.2 0.070
      Proximal resection margin (cm) 12.1±10.7 23.7±13.5 <0.001
      Distal resection margin (cm) 9.9±8.8 13.3±12.1 0.001
      Length of specimen (cm) 21.8±15.5 36.8±15.3 <0.001
      Lymphatic invasiona 0.825
       No 582 (50.7) 78 (51.7)
       Yes 566 (49.3) 73 (48.3)
      Venous invasiona 0.145
       No 833 (72.6) 118 (78.1)
       Yes 315 (27.4) 33 (21.9)
      Perineural invasiona 0.340
       No 487 (42.4) 70 (46.7)
       Yes 661 (57.6) 80 (53.3)
      Recurrence pattern No. of patients (%) P-value
      Nontransverse colon cancer (n=1,151) Transverse colon cancer (n=151)
      Locoregional recurrence 23 (2.0) 12 (7.9) <0.001
       Near the anastomotic site 12 (1.0) 1 (0.7)
       Regional lymph nodes 4 (0.3) 10 (6.6)
       Peritoneal recurrence around the primary tumor 7 (0.6) 1 (0.7)
      Systemic recurrencea 126 (10.9) 19 (12.6) 0.548
       Liver 48 (4.2) 8 (5.3)
       Lung 48 (4.2) 8 (5.3)
       Distant lymph nodes 19 (1.7) 4 (2.6)
       Multiple peritoneal seeding 17 (1.5) 1 (0.7)
       Otherb 12 (1.0) 3 (2.0)
      Variable Univariate analysis Multivariate analysis
      HR (95% CI) P-value HR (95% CI) P-value
      Age >65 yr 1.192 (0.608–2.335) 0.609 1.144 (0.582–2.246) 0.697
      Female sex 1.032 (0.530–2.006) 0.927 1.024 (0.522–2.011) 0.945
      ASA physical status III–IV 1.695 (0.657–4.368) 0.275
      CEA >5 ng/mL 1.191 (0.567–2.502) 0.644
      Transverse colon 4.130 (2.055–8.299) <0.001 4.513 (2.226–9.154) <0.001
      T3–T4 category 5.733 (0.785–41.883) 0.085 4.220 (0.569–31.325) 0.159
      N2 category 1.985 (1.021–3.860) 0.043 2.044 (1.034–4.042) 0.040
      Adjuvant chemotherapy 2.146 (0.831–5.539) 0.114
      Proximal resection margin <5 cm 0.381 (0.091–1.586) 0.185
      Distal resection margin <5 cm 1.029 (0.518–2.043) 0.935
      Lymphatic invasion 2.004 (0.997–4.028) 0.051
      Venous invasion 2.122 (1.087–4.145) 0.028
      Perineural invasion 2.570 (1.168–5.658) 0.019
      Table 1. Baseline characteristics (n=1,302)

      Values are presented as mean±standard deviation, number (%), or median (interquartile range).

      BMI, body mass index; ASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen

      Table 2. Pathological data (n=1,302)

      Values are presented as number (%) or mean±standard deviation.

      Data on lymphatic, venous, and perineural invasion were unavailable for 3 patients in the nontransverse colon cancer group, and perineural invasion data were unavailable for 1 patient in the transverse colon cancer group, due to incomplete pathological records.

      Table 3. Recurrence patterns by colon cancer location (n=1,302)

      Combined systemic and locoregional recurrence was detected in 8 patients in the nontransverse colon cancer group and in 4 patients in the transverse colon cancer group.

      aPatients could have recurrence at more than one systemic site. bIncluding the ovaries, spleen, small bowel, adrenal gland, ureter, and bone.

      Table 4. Univariate and multivariate Cox regression analysis for locoregional recurrence

      Lymphatic, venous, and perineural invasion were excluded from the multivariate analysis to avoid potential multicollinearity in consideration of the limited number of events.

      HR, hazard ratio; CI, confidence interval; ASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen.


      Ann Coloproctol : Annals of Coloproctology Twitter Facebook
      TOP